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Abstract: Same-sex female couples who wish to become pregnant can choose donor insemination or
in-vitro fertilization (IVF)—a technique intended for infertile women. In general, women in same-sex
female partnerships are no more likely to be infertile than those in opposite sex partnerships. This
article investigates data available from the Government Regulator of UK fertility clinics—the Human
Fertilization and Embryology Authority, which is the only data available worldwide on same-sex
female couples and their fertility choices. IVF is increasing both in absolute numbers and relative
proportions year on year in the UK, compared to licensed donor insemination for same-sex female
couples. As IVF has greater human and financial costs than donor insemination, policies should
not encourage it as the first choice for fertile women requiring sperm. Commercial transactions are
taking place where fertile lesbians receive cut price, and arguably unnecessary, IVF intervention
in exchange for selling their eggs to be used for other infertile customers. If women are not told
about the efficacy of fresh vs. frozen semen, and the risks of egg ‘sharing’ or intra-couple donation,
exploitation becomes possible.
Keywords: same sex female couples; lesbians; bisexual women; IVF; donor insemination;
pregnancy choices
1. Introduction
A woman in a same-sex couple who wishes to have a baby will need to use an egg
and sperm from somewhere. The options in the UK are:
1. Her own egg, and fresh sperm from a known male or unknown one found online,
using an informal, unregulated arrangement
2. Her own egg, and sperm (usually frozen) from a formal, regulated healthcare operator
(National Health Service (NHS) or private, including located abroad)
3. Her partner’s egg, and sperm (usually frozen) from a formal, regulated healthcare
operator (NHS or private, including located abroad)
4. A third-party donated egg, and sperm (usually frozen) from a formal regulated
healthcare operator (NHS or private, including located abroad)
All options contain uncertainties.
Option 1 may be viewed as preferable by some due to being cheaper and less invasive.
It uses home insemination and fresh semen (which has greater success than frozen [1],
relationships rely on trust, and the child usually knows its origins, but few resources exist
for General Practitioners (GPs) or clinics to discuss the options [2]). By contrast, options 2–4
use formal, regulated healthcare operators and have the qualities of a rigorous assessment
process, medical advice and involvement, controlled environments, and contractual legality,
thus entailing greater cost.
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Option 2 can be done in two ways. The first (2a) is where washed sperm is inserted
into the genetic and gestational mother’s uterus using an intra-uterine cannula, a procedure
known as donor insemination–intra-uterine insemination (DI-IUI). This procedure can
be done with or without ovarian stimulation. If frozen sperm is used, intracytoplasmic
sperm injection (ICSI) is more likely to be needed. The side effects of DI-IUI without
stimulation are minimal; some women may experience stomach cramps similar to period
pains. With stimulated cycles (timed ovulation induction), side effects include bruising,
bloating, constipation, breast tenderness, and moodiness. This option is also associated
with an increased risk of multiple pregnancy. Option 2a costs around £800–£1300 per cycle.
Alternatively (2b), in-vitro fertilisation (IVF) can be used. In IVF, ovulation is stim-
ulated and controlled by drugs, ova are extracted under transvaginal ultrasound control
from the mature follicles growing in the woman’s ovaries and combined with donated
sperm in a laboratory dish, or by using ICSI. The resulting embryo(s) are then transplanted
back into her uterus. Spare embryos may also be frozen to be used in the future, or do-
nated to medical research or another couple. IVF is not directly comparable to DI, partly
because hyperstimulation is used to increase the numbers of eggs compared to natural
or timed cycles in DI, and partly because of occasional multiple embryo transfers. With
IVF there is control over the number of embryos transferred, and spare embryos might be
cryopreserved. Option 2b costs around £5000–£7000 per cycle depending on protocol and
medication used. Women may be less likely to undergo as many repeat IVFs as DIs given
that it is more successful but also more costly.
The side effects and complications of IVF, although decreasing in frequency with
more modern protocols, include hot flushes, allergic reactions, and complications of the
drugs, including ovarian hyperstimulation syndrome (OHSS), depression or irritability,
vaginal bleeding, blood in urine, bloating, breast tenderness, bruising from injections,
cramping, headaches, restlessness, pelvic pain, and constipation. These can persist for
years in some women, for example if the IVF triggers depression [3], or be lifelong for
children, for example if they suffer prematurity-related morbidities after IVF [4] that
happen with single embryo transfer but especially with multiple pregnancy [5]. Adverse
pregnancy outcomes are also increased, especially relating to multiple births. Severe
OHSS occurs in approximately 1.4 % of all cycles [6] and cases have appeared in the
past in the Confidential Enquiry into Maternal Deaths [7]. The rate of a wide variety of
perinatal adverse events following IVF side effects is around double that of spontaneous
conceptions [4,8]. Longer term, there is uncertainty about an association between IVF and
borderline ovarian tumors [9] and endometrial tumors [10].
In option 3, IVF is also used, but one woman’s embryo is transferred into her part-
ner’s uterus after she too has been primed with drugs. A woman who undergoes egg
collection completes HFEA (Human Fertilisation and Embryology Authority) paperwork
as a donor, and the woman who undergoes embryo transfer completes paperwork as
a patient undergoing double donor IVF. The substantially greater physical risks of any
pregnancy are taken by the embryo recipient. In addition, obstetric complications may
arise because of increased genetic incompatibility between gestational mother and fetus
who are now 100% (rather than 50%) unalike, in particular diseases such as preeclampsia
with its almost five-fold increase in risk [11]. This procedure costs around £8000–£9000 per
cycle plus extras.
Option 4 is used where the woman herself is infertile and Option 3 is not possible
or desired. Around one in seven UK couples may have difficulty conceiving [10]. When
age differences are taken into account, there are reportedly few differences in fertility rates
in lesbians compared to heterosexual women [12]. A recent systematic review found that
pregnancy rates were similar or higher in lesbians than heterosexual women after DI [13].
In an ideal world, we would have information on: all of the routes taken by same-sex
female couples; the success rates per procedure and per woman; multiple birth rates; and
side effects of each treatment, especially the regulated options 2–4. We would also have
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information on trans and non-binary people and their routes to medically-assisted preg-
nancy.
The Human Fertilisation and Embryology Authority (HFEA) is the UK Government’s
regulatory body responsible for ensuring fertility clinics comply with UK law. It collects
data from all UK fertility clinics and publishes an annual report and accompanying data
sheet. The HFEA found little difference in birth rates between same-sex and opposite-sex
couples after donor insemination (DI) [14]. The HFEA does not collect data separately on
trans and non-binary people and their interactions with fertility clinics, these are included
in the generic data.
2. Materials and Methods
This project is secondary data analysis of freely available data on fertility trends in the
UK. The data is provided by the HFEA at their website [14–16]. Data were downloaded
from their most recent spreadsheet, relating to data collected by them up to 2019. We
analyzed these data in an Excel spreadsheet and percentages were derived. Members of
a support group for LGBT+ women & people worldwide on the path to motherhood or
parenthood were consulted by the Lead Contact (L-R T) asking about their recent experi-
ences of UK fertility clinics as an informal service evaluation and for hypothesis generation.
Comments contributed were constructed into a range of typical, illustrative stories.
3. Results
3.1. Fertility Trends
For option 1 above, there is no information regarding pregnancy rates for same-sex
female couples using private arrangements with men who donate fresh sperm. Fresh
sperm is deposited by the cervix whereas frozen clinic sperm is thawed then instilled into
the uterus via a catheter. There is no clear evidence as to which route for frozen sperm has
better success rates [17]. Long ago, fresh DI was shown to be three-fold better in achieving
pregnancy than frozen DI for infertile women used as their own controls [3]. Logically,
using fresh, recently produced semen at the time of ovulation would also be expected to
have success rates similar to a natural background in fertile (or untested) women, and better
success rates per intervention than in current HFEA data of 13.8% (unstimulated) and 15.2%
(stimulated) with frozen sperm (option 2a), and 27.8% with IVF (options 2b—patient’s egg,
donor sperm) and 36.6% with options 3–4 (donor egg and donor sperm) [15].
The numbers of same-sex female couples using DI and IVF are increasing overall.
Fewer same sex female couples are now receiving DI-IUI than IVF (see Table 1). The HFEA
report from 2019 [16] included data up to 2017 and stated that there is “an upward trend
in the use of IVF by patients in same-sex partnerships [and also for single women with
no partner] and clinicians recommending trying IVF before DI”. Their Family Formations
Report [14] states that “Historically, most patients in same-sex relationships . . . have
used DI, as these patients are likely seeking treatment to access donor sperm rather than
for infertility reasons.” It also states that “almost 60% of patients in female same-sex
relationships seeking fertility treatment started IVF without any prior DI cycles in 2018”. It
notes that “The increased use of IVF may relate to the higher birth rate of IVF compared to
DI and to the added cost of undergoing multiple rounds of DI cycles to achieve a birth.”
The HFEA datasheet [15] gives the proportions of patients experiencing adverse
events from IVF and DI treatment. These include miscarriages, ectopic pregnancies, het-
erotopic, biochemical, and molar. In 2019, with IVF, of 22,866 pregnancies there were
2657 miscarriages (11.7%), 235 ectopic pregnancies (1.0%), and 4319 biochemical adverse
events (18.9%); with DI of 987 pregnancies, there were 103 miscarriages (10.4%), 11 ectopic
pregnancies (1.1%), and 109 biochemical adverse events (11.0%).
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Table 1. Numbers of patients and in-vitro fertilisation (IVF) and donor insemination (DI) treatment cycles with relative proportions.
Year of
Treatment
Numbers of DI Treatment
Cycles for Women with
Female Partner
Numbers of Patients in
Same-Sex Female
Couples Receiving DI
Numbers of IVF Treatment
Cycles for Women with
Female Partner
Numbers of Patients in
Same-Sex Female
Couples Receiving IVF
Proportions of DI and
IVF Intervention Cycles
DI% IVF%
Proportions of DI and
IVF Patients
DI% IVF%
2000 441 194 38 30 92.1 7.9 86.6 13.4
2001 585 214 46 32 92.7 7.3 87.0 13.0
2002 655 251 86 61 88.4 11.6 80.4 19.6
2003 720 291 85 66 89.4 10.6 81.5 18.5
2004 943 368 99 73 90.5 9.5 83.4 16.6
2005 873 376 151 121 85.3 14.7 75.7 24.3
2006 866 363 199 151 81.3 18.7 70.6 29.4
2007 708 322 261 184 73.1 26.9 63.6 36.4
2008 896 405 331 250 73.0 27.0 61.8 38.2
2009 984 469 489 352 66.8 33.2 57.1 42.9
2010 1091 559 588 437 65.0 35.0 56.1 43.9
2011 1310 641 789 579 62.4 37.6 52.5 47.5
2012 1484 743 943 694 61.1 38.9 51.7 48.3
2013 1533 789 1092 803 58.4 41.6 49.6 50.4
2014 1845 944 1331 986 58.1 41.9 48.9 51.1
2015 2065 1051 1461 1091 58.6 41.4 49.1 50.9
2016 2298 1125 1735 1249 57.0 43.0 47.4 52.6
2017 2517 1333 2044 1451 55.2 44.8 47.9 52.1
2018 2616 1346 2203 1574 54.3 45.7 46.1 53.9
2019 2514 1313 2435 1688 50.8 49.2 43.8 56.2
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The average age of IVF is now lower in same-sex than opposite-sex couples (34.9 vs.
35.6 years). The two types of IVF within a same-sex female couple, when the egg from one
woman is used within her own or her partner’s uterus, are not distinguished in the HFEA
dataset because the donor egg could come from a partner or another donor. The proportion
of same-sex female couple procedures that may be intra-partner egg donation is unclear.
A review of statistics from other countries yielded no relevant information. The
Canadian Assisted Reproductive Technologies Register (CARTR) report based on data
submitted by clinics to the CARTR Plus database mentions reasons for treatment including
“no male partner” but no further clarification [18]. The USA National Center for Chronic
Disease Prevention and Health Promotion Assisted Reproduction Success Report 2017 does
not include same-sex female couples as a reason for using assisted reproduction techniques
(ART) [19] and there do not appear to be any statistics about this on their website. The
European Society of Human Reproduction and Embryology core dataset does not include
partner sex so cannot be used to find ART data for same-sex female couples [20]. So, the
data presented here may be the only information available worldwide on rates of IVF and
DI in same-sex female couples.
3.2. Personal Experiences
The following three reconstructed stories summarize scenarios typical of a range
of feedback to the LGBT Mummies Tribe from same-sex female couples around their
experiences of using fertility clinics and using IVF rather than DI-IUI.
Couple 1: They said they felt “steered” towards IVF rather than DI-IUI, IUI was hardly
spoken about and dismissed, and that IVF was the quickest & best option, even though
they had no fertility issues.
Couple 2. They said they attended their clinic with the idea of IVF in mind due to
wanting to achieve a pregnancy quickly. The clinic gave them their options of both DI-IUI
& IVF. They said they felt that the clinic covered the risks of both, and success rates equally.
They decided to go for IVF because they were aware of DI-IUI taking longer, and felt that
their clinic was helpful in regards to giving them options around the different routes to
take. They were happy with the service they received.
Couple 3: The clinic did not talk about DI-IUI at all, they only sold IVF at the open
evening. The couple then wanted to do ‘reciprocal’ IVF and the clinic advised they could
‘egg share’ and provide eggs for someone else. They did not receive any guidance or
information relating to the risks of egg sharing. They were told that it was a ‘package deal’,
so if they participated, it meant they got treatment for £500. Later, they received multiple
bills for hidden fees. ICSI was performed without their knowledge. The couple fought
this for months before the charge was removed. With the second round of egg sharing,
the clinic refused to do a fresh transfer and said frozen was better due to her having the
complication of OHSS.
“We felt lied to, and that I was just being exploited and harvested for heterosexuals who
needed the eggs. The fact that if I didn’t produce 12 eggs or more, meant we had to pay
the full amount instead of the £500 for the treatment, meant additional stress on us, & at
no point were we told of any risks with egg sharing—we did egg sharing 3 times.”
4. Discussion
UK National Institute of Health and Care Excellence (NICE) guidelines recommend
that women aged under 40 years who have not conceived after 2 years of regular unpro-
tected heterosexual intercourse or 12 cycles of artificial insemination (where six or more
are by DI-IUI) should be offered IVF [21]. Like most fertility services, this is affected by
local commissioning arrangements. Given this requirement, it is unlikely that same-sex
female couples will be referred to an NHS clinic for a new appointment.
So, if a same-sex female couple attends a private fertility clinic as a new appointment,
they may be presented with the option to decide between paying for donor sperm (Option
2a) or to consider the much more invasive and costly IVF (Options 2b-4). They should be
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informed of the risks and side effects of IVF regarding Option 2b or Option 3, or whether
they need to use Option 4 because of infertility. If they were unaware of the efficacy of
home insemination (Option 1), they might never have needed any medical involvement in
the first place. However, the couple should also be advised to seek legal advice regarding
what happens in the event of breakdown of trust. With home insemination, the sperm
donor has legal right to access the child and can be pursued for maintenance, unless legal
procedures are completed correctly before conception takes place, so that the requirements
are met for legal parenthood to be established for the recipient and partner at the point of
conception. Fertility clinics have established processes to complete this for their clients.
Additionally, the legal change in April 2005 requiring sperm donors to provide their
personal details in order for the child to know its origins, has meant that same-sex female
couples purchasing sperm can now only do this via a regulated clinic. As couples cannot
legally purchase sperm from abroad to be delivered direct to their home, this may have
several consequences such as the financial pressure on low-waged lesbians to opt for a
1-night stand strategy; increased use of IVF clinics abroad; and same-sex female couples
being persuaded by clinics to opt for more invasive and expensive treatments, possibly
with discounted terms and arrangements. Possibly because of this legal change requiring
sperm donors to provide personal details, donor sperm is in short supply and is relatively
expensive (£1000 per sample). This is another factor that may be pushing same-sex female
couples towards IVF; multiple samples of sperm may be needed to complete the several
cycles of DI possibly required to achieve pregnancy, whereas fewer may be needed for IVF.
Another possibility is that a woman in a same-sex couple may object to having sperm in
her vagina, although there is no evidence about this. This would be expected to remain
relatively constant so would not explain the rise in IVF proportions.
Reasons why the relative proportions of DI vs IVF treatments are gradually falling
might include patient choice, legal changes, financial concerns, relative success rates, and
advertising amongst others. It is unlikely that the explanation for same-sex female couples
opting for IVF more than ever before is an increase in their underlying medical infertility
over the 2 decades in question. Financially, couples have to make a choice between paying
for several attempts at DI first because they are not always eligible for NHS treatment (as
eligibility criteria vary across the country), or for one or more IVF cycles. DI has lower
individual success rates per cycle than IVF but costs less per attempt. Per cycle, pregnancy
is more likely to have higher live birth rates with IVF than DI, but finances may limit the
number of attempts. Although there is no evidence regarding lesbians’ views, clinicians
may consider that there will be accumulating stress after repeated IUI failures and counsel
accordingly. They may be concerned (as may patients) about the time-to-pregnancy as
a crucial quality indicator, and then put this into routine counselling discussions. There
is a fine line between patient choice based on non-directive counselling and ‘doctor-led
behavior’. A market is made up of buyers and sellers who both have influence. Part of
the change may be driven by couples themselves, their preferences, or their own financial
constraints, and not by the clinics. However, these customers rely on the descriptions of
the products and their doctors’ beliefs and recommendations.
There are higher risks and worse side effects with IVF than DI. If a woman is ap-
proaching 40 years old, if DI has failed, or if she is unwilling to undergo six cycles of DI
first, then IVF may be appropriate. Women may be less likely to have as many repeat IVFs,
given that it is more onerous and costly. The rise in IVF proportions may also be due to
clinics promoting IVF as being much safer than in the past. For example, there are lower
rates of OHSS. Doctors may be keen to offer pre-implantation genetic screening before
pregnancy, in order to reassure couples about the presence of aneuploidy. Techniques of
embryo cryopreservation (vitrification) have improved, allowing more future options, but
also at a price. The age of people seeking parenthood is steadily increasing overall, and
higher age reduces success rates, particularly for DI. However, the average age of same sex
female couples in the HFEA dataset is gradually reducing, from 35.5 (SD 4.8) in 2000 to
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34.8 (SD 4.5) in 2019, for women receiving IVF, and 34.4 (SD 4.5) in 2000 to 33.2 (SD 4.2) in
2019 for women receiving DI [15].
Couples sometimes select IVF for its possibility for intra-partner egg donation [12],
which is often presented as a romantic way to conceive a baby within a female couple. The
narrative is that both partners have some biological connection with their child, which is
a powerful psychological, emotional, and social motivator. Websites frequently present
an encouraging view of this so-called ‘reciprocal’ or ‘partner IVF’ process [22]. Medically,
this is an intra-couple altruistic egg donation arrangement, involving medical third-parties
and three different biological providers (of egg, sperm, and uterus), which carries higher
obstetric risk to the non-genetically-related woman. There is an ethical issue for the doctor
here, it is not a simple consumer choice.
In some clinics, a woman being hyperstimulated to donate eggs, including to her
partner through IVF, can also give eggs away in order to get reduced fee treatment. This is
referred to as “egg-sharing” and is presented as a reasonable commercial arrangement with
fertility companies, who “harvest” eggs from fertile women in exchange for IVF. Unlike
other forms of egg “bartering” or “selling” [23], clinics may be particularly interested in
obtaining lesbians’ eggs, as it appears they achieve higher pregnancy rates for recipients,
maybe unsurprisingly given that few donors are medically infertile. Only women aged
under 35 can “egg share”. Thus, in order to obtain the associated financial discount, women
averaging age 34 may feel they have insufficient time to try several DI cycles first before
opting for IVF. Commercial pressures also exist in a profit-driven industry that has a severe
shortage of eggs for heterosexual couples suffering largely with age-related or unexplained
infertility. The (usually older and heterosexual) woman who is the egg-sharing recipient
may also not have been told about the extra risks of an ovum recipient pregnancy and she
too may suffer avoidable, iatrogenic complications.
Overall, excess and unnecessary use of IVF may incur avoidable side effects and
complications, including maternal death [24,25]. Fertility clinics effectively offset the full
human and financial costs of IVF, as the NHS deals with the side effects and poor outcomes,
including treatment of pre-eclampsia, multiple births, depression, and prematurity-related
morbidities in the child. If the number of women using IVF is increasing, it will inevitably
have a detrimental effect on women, children, and the NHS, not the fertility clinics, their
staff, or shareholders.
5. Conclusions
Same-sex female couples who wish to have a baby and use formal fertility clinic
services can choose between DI and IVF in the private sector. Both have advantages and
disadvantages. The rates of DI relative to IVF interventions are falling, but the reasons
why are not straightforward or clear. They may relate more to fertility clinic-led initiatives,
patient choice, and commercial pressures rather than medical need. The clinics have a
duty of care and are legally bound by the HFEA code of practice to provide patients with
full information about the treatments available and attendant medical risks. Clinics must
put patients first, rather than their own commercial interests. The HFEA should improve
reporting, examine individual clinic practices, and ensure compliance.
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